Biotechpharma UAB. (4/14/17). "Press Release: Biotechpharma Further Expands GMP Manufacturing Capacity". Vilnius.

	Region	Vilnius
	Country	Lithuania
	Organisation	Biotechpharma UAB
	Group	Northway (Group)
	Product	contract manufacturing (biologicals)
	Product 2	recombinant protein production in mammalian cells
	Person	Bumelis, Vladas Algirdas (Northway 201812– Board Chairman of Biotechpharma UAB before CEO + Founder of Biotechpharma)

Biotechpharma UAB, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals announced the completion of the expansion of its cGMP facility.

The facility expansion contains a separate 2,000 L mammalian production line with a seeding train consisting of 10 L, 50 L and 500 L bioreactors. “Adding an additional 2,000 L to our existing 1000 L line will enable us to meet the continuously growing demand for manufacturing of monoclonal antibodies and mammalian-cell derived products. It will also increase our flexibility by allowing us to run two large scale processes in parallel” commented Dr. Vladas Bumelis, Chief Executive Officer of Biotechpharma.

Biotechpharma also completed it’s new cGMP-Pilot Plant for both microbial and mammalian products. “While producing recombinant proteins and monoclonal antibodies in our large scale cGMP-facility, we noted a growing demand from our clients for small scale GMP-production. Biotechpharma can now offer small scale GMP-manufacturing in short timeframes and for competitive pricing, if clients need only small amounts of GMP material for their initial pre-clinical or clinical studies” Dr. Vladas Bumelis added. The new Pilot Plant includes GMP-certified clean rooms for drug substance manufacturing at 10 to 50 L scale in disposable bioreactors for mammalian cell-based production, and 1 to 10 L scale for microbial production. The new pilot-plant will also be used for Master Cell Bank and Working Cell Bank cGMP-manufacturing

About Biotechpharma UAB

Biotechpharma UAB, based in Vilnius, Lithuania, is a fast growing contract development and manufacturing organization (CDMO) for biopharmaceuticals. Utilizing a one-stop-shop concept Biotechpharma provides a full range of services from cloning, to GMP-manufacturing of drug substance and drug product. Biotechpharma’s clients include biotech companies, world known academic institutions and multinational pharmaceutical companies from Europe, North America and Asia. State-of-the-art quality, flexibility, innovative thinking and high execution speed, ensure meeting and exceeding our clients’ expectations. Biotechpharma is a privately owned company employing 130 people.

Record changed: 2023-06-05